Susan Blumel

407 total citations
16 papers, 308 citations indexed

About

Susan Blumel is a scholar working on Genetics, Pathology and Forensic Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Susan Blumel has authored 16 papers receiving a total of 308 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Genetics, 12 papers in Pathology and Forensic Medicine and 5 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Susan Blumel's work include Chronic Lymphocytic Leukemia Research (14 papers), Lymphoma Diagnosis and Treatment (12 papers) and Monoclonal and Polyclonal Antibodies Research (5 papers). Susan Blumel is often cited by papers focused on Chronic Lymphocytic Leukemia Research (14 papers), Lymphoma Diagnosis and Treatment (12 papers) and Monoclonal and Polyclonal Antibodies Research (5 papers). Susan Blumel collaborates with scholars based in United States. Susan Blumel's co-authors include Julie M. Vose, Faith Young, Jennifer L. Kelly, John P. Leonard, Richard I. Fisher, Jonathan W. Friedberg, Jamés O. Armitage, Derick R. Peterson, Steven Grant and Steven H. Bernstein and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Susan Blumel

16 papers receiving 302 citations

Peers

Countries citing papers authored by Susan Blumel

Since Specialization

Citations

This map shows the geographic impact of Susan Blumel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Susan Blumel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Susan Blumel more than expected).

Fields of papers citing papers by Susan Blumel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Susan Blumel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Susan Blumel. The network helps show where Susan Blumel may publish in the future.

Co-authorship network of co-authors of Susan Blumel

This figure shows the co-authorship network connecting the top 25 collaborators of Susan Blumel. A scholar is included among the top collaborators of Susan Blumel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Susan Blumel. Susan Blumel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	A PHASE IIA STUDY EVALUATING THE SAFETY AND TOLERABILITY OF UMBRALISIB AND IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA 2019 ·Hematological Oncology ·Matthew A. Lunning, Philip J. Bierman, R. Gregory Bociek, Jamés O. Armitage, (unknown), Susan Blumel, (unknown), (unknown), Julie M. Vose	2
2	Combination of Umbralisib, Ublituximab, and Bendamustine Is Safe and Highly Active in Patients with Advanced Diffuse Large B-Cell Lymphoma and Follicular Lymphoma 2018 ·Blood ·Matthew A. Lunning, Philip J. Bierman, R. Gregory Bociek, Marshall T. Schreeder, Tanya Siddiqi, Christopher R. Flowers, Jonathon B. Cohen, Susan Blumel, (unknown), (unknown), Peter Sportelli, Hari P. Miskin, Michael Weiss, Julie M. Vose	1
3	COMBINATION OF TGR‐1202, UBLITUXIMAB, AND BENDAMUSTINE IS SAFE AND HIGHLY ACTIVE IN PATIENTS WITH ADVANCED DLBCL AND FOLLICULAR LYMPHOMA. 2017 ·Hematological Oncology ·Matthew A. Lunning, Julie M. Vose, Philip J. Bierman, Gregory Bociek, Marshall T. Schreeder, Tanya Siddiqi, Susan Blumel, (unknown), (unknown), (unknown), Peter Sportelli, Hari P. Miskin, Michelle Purdom, Michael Weiss, Nathan Fowler	4
4	Combination of Ublituximab, TGR-1202, and Bendamustine Demonstrates Significant Activity in Patients with Advanced DLBCL and Follicular Lymphoma 2016 ·Blood ·Matthew A. Lunning, Philip J. Bierman, R. Gregory Bociek, Marshall T. Schreeder, Susan Blumel, (unknown), (unknown), Peter Sportelli, Hari P. Miskin, Michael Weiss, Julie M. Vose	2
5	Safety and activity of the chemotherapy-free triplet of ublituximab, TGR-1202, and ibrutinib in relapsed B-cell malignancies. 2015 ·Journal of Clinical Oncology ·Nathan Fowler, Loretta J. Nastoupil, Matthew A. Lunning, Julie M. Vose, Tanya Siddiqi, Christopher R. Flowers, Jonathon B. Cohen, Marshall T. Schreeder, (unknown), Susan Blumel, (unknown), (unknown), (unknown), (unknown), Peter Sportelli, Hari P. Miskin, Michael Weiss, Swaroop Vakkalanka, Srikant Viswanadha, Susan O’Brien	9
6	Ublituximab + TGR-1202 Demonstrates Activity and a Favorable Safety Profile in Relapsed/Refractory B-Cell NHL and High-Risk CLL: Phase I Results 2015 ·Blood ·Matthew A. Lunning, Julie M. Vose, Nathan Fowler, Loretta J. Nastoupil, Jan A. Burger, William G. Wierda, Marshall T. Schreeder, Tanya Siddiqi, Christopher R. Flowers, Jonathon B. Cohen, Susan Blumel, (unknown), (unknown), (unknown), (unknown), Peter Sportelli, Hari P. Miskin, Michael Weiss, Susan O’Brien	6
7	Ublituximab plus TGR-1202 activity and safety profile in relapsed/refractory B-cell NHL and high-risk CLL. 2015 ·Journal of Clinical Oncology ·Matthew A. Lunning, Julie M. Vose, Nathan Fowler, Loretta J. Nastoupil, Marshall T. Schreeder, Tanya Siddiqi, Christopher R. Flowers, Jonathon B. Cohen, Susan Blumel, (unknown), (unknown), (unknown), (unknown), Peter Sportelli, Hari P. Miskin, Michael Weiss, Swaroop Vakkalanka, Srikant Viswanadha, Susan O’Brien	5
8	Approaches to Managing Safety With Lenalidomide in Hematologic Malignancies 2014 ·Journal of the Advanced Practitioner in Oncology ·Susan Blumel, (unknown)	7
9	Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Combination with TGR-1202, a Next Generation Once Daily PI3kδ Inhibitor, Demonstrates Activity in Heavily Pre-Treated and High-Risk Chronic Lymphocytic Leukemia (CLL) and B-Cell Lymphoma 2014 ·Blood ·Matthew A. Lunning, Julie M. Vose, Marshall T. Schreeder, Nathan Fowler, Loretta J. Nastoupil, Tanya Siddiqi, Susan Blumel, (unknown), (unknown), (unknown), Hari P. Miskin, Peter Sportelli, Michael Weiss, Swaroop Vakkalanka, Srikant Viswanadha, Susan O’Brien	9
10	The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma 2011 ·Blood ·Jonathan W. Friedberg, Julie M. Vose, Jennifer L. Kelly, Faith Young, Steven H. Bernstein, Derick R. Peterson, (unknown), Susan Blumel, (unknown), Jane L. Liesveld, Richard I. Fisher, Jamés O. Armitage, Steven Grant, John P. Leonard	138
11	Time to Treatment Response in Patients with Follicular Lymphoma Treated with Bortezomib Is Longer Compared with Other Histologic Subtypes 2010 ·Clinical Cancer Research ·Owen A. O’Connor, Carol S. Portlock, Craig H. Moskowitz, Paul A. Hamlin, David J. Straus, John F. Gerecitano, Mithat Gönen, (unknown), Debra Sarasohn, (unknown), Ellen Neylon, (unknown), Susan Blumel, Andrew M. Evens, Andrew D. Zelenetz, James R. Wright, Brenda Cooper, Jane N. Winter, Julie M. Vose	36
12	Patients with chemotherapy‐refractory mantle cell lymphoma experience high response rates and identical progression‐free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre phase 2 clinical trial 2009 ·British Journal of Haematology ·Owen A. O’Connor, Craig H. Moskowitz, Carol S. Portlock, Paul A. Hamlin, David J. Straus, (unknown), Debra Sarasohn, Mithat Gönen, (unknown), Ellen Neylon, (unknown), (unknown), Susan Blumel, Andrew D. Zelenetz, Leo I. Gordon, James R. Wright, Julie M. Vose, Brenda Cooper, Jane N. Winter	59
13	The role of bendamustine in the treatment of indolent non-Hodgkin lymphoma 2009 ·Cancer Management and Research ·Ibrahim Aldoss, Susan Blumel, Philip J. Bierman	1
14	Bendamustine: A Novel Cytotoxic Agent for Hematologic Malignancies 2008 ·Clinical journal of oncology nursing ·Susan Blumel, Amy Goodrich, (unknown), Nam H. Dang	9
15	Patient-Specific Vaccine Therapy for Non-Hodgkin Lymphoma 2005 ·Clinical journal of oncology nursing ·(unknown), Susan E. King, J. M. Fiore, (unknown), Susan Blumel	4
16	A Multicenter Experience with Single Agent Bortezomib in Non-Hodgkin’s Lymphoma Reveals Marked Differences in Sub-Type Sensitivity to Proteasome Inhibition. 2004 ·Blood ·Owen A. O’Connor, James R. Wright, Craig H. Moskowitz, Barbara MacGregor‐Cortelli, David J. Straus, Andrew Evans, Jane N. Winter, Omer N. Koç, N. Horvath, Susan Blumel, Julie M. Vose, David P. Schenkein, Andrew D. Zelenetz	16

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact